medigraphic.com

2010, Número 1

<< Anterior Siguiente >>

Rev Hematol Mex 2010; 11 (1)


Guías mexicanas de diagnóstico y recomendaciones terapéuticas para mieloma múltiple (2009)

Gómez-Almaguer D, Cano-Castellanos R, Cedillo-de la Cerda JL, Garcés-Ruíz OM, Gómez-Almaguer D Limón-Flores A, López-Hernández M, Martínez-Baños D, May-Magaña EM, Nambo-Lucio MJ, Rivas-Vera S, Ruiz-Argüelles GJ, Sobrevilla-Calvo P, Vela-Ojeda J, Villalobos-Prieto A, Zárate-Rodríguez PA

Idioma: Español
Referencias bibliográficas: 74
Paginas: 40-62
Archivo PDF: 204.70 Kb.


RESUMEN

El mieloma múltiple es una neoplasia de células plasmáticas malignas que pueden sintetizar inmunoglobulinas. Es incurable, poco frecuente y su tratamiento es heterogéneo en las diferentes instituciones y centros privados de nuestro país. En varias ocasiones se reunió un grupo de hematólogos mexicanos para revisar los criterios internacionales del diagnóstico y tratamiento de este padecimiento, con el fin de comparar y complementar los propios, los cuales incluirían diagnóstico, diagnóstico diferencial, terapia de inducción, evaluación de la respuesta a la terapia, etc. Las recomendaciones de este grupo se basaron en las guías americanas y europeas al respecto, y se adaptaron a la práctica médica de México.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21-33.

  2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520.

  3. National Comprehensive Cancer Network (NCCN), Multiple Myeloma. Practice Guidelines in Oncology, 2007. Available from: http://www.nccn.og/professionals/physician_gls/PDF/myeloma.pdf

  4. Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, et al. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132:410-451.

  5. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Genetic predisposition for monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2008; 83:601-603.

  6. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar Romero L. Multiple myeloma in Mexico: A single institution, twenty-year experience. Arch Med Res 2004, 35: 163-167.

  7. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 2009; 113:5412-7.

  8. Dispenzieri A, Rajkumar VS, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of Newly Diagnosed Multiple Myeloma based on Mayo Stratification of Myeloma and riskadapted Therapy (mSMART): Consensus Statement. Mayo Clin Proc 2007; 82:323-41.

  9. Stewart A, Bergsagel P, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529-534.

  10. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International Staging System for Multiple Myeloma. J Clin Oncol 2005; 23:3412-3420.

  11. IMWG. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-757.

  12. Raabs MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple Myeloma. Lancet 2009; 374:324-339.

  13. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley, JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J of Haematol 2003; 122: 441-450.

  14. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplantation 1998; 102:1115-1123.

  15. Durie BG, Harousseau JL, San Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

  16. Rajkumar SV, San Miguel JF 2009 Guidelines for the Uniform Reporting of Clinical Trials: Report of the 2008 International Myeloma Workshop Consensus Panel I. Available from: http://www.mw-delhi09.com/spargoProgramPresentationDetails.asp

  17. Kato T, Tsukamoto E, Nishioka T, Yamazaki A, Shirato H, Kobayashi S, et al. Early detection of bone marrow involvement in extramedullary plasma-cytoma by whole-body F-18 FDG position emission tomography. Clin Nucl Med 2000; 25: 870-873.

  18. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice G, Mehta A. Fluoro-deoxyglucose position emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002; 117:133-135.

  19. Schirmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003; 18: 841-845.

  20. Abstracts Erythropoietin treatment of anemia associated with multiple myeloma, available from:http://www.faqs.org/abstracts/Health/Erythropoietin-treatment-of-anemia-associatedwith-multiple-myeloma.html

  21. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Uri H, Amos C. Recombinant Human Erythropoietin in the Treatment of Multiple Myeloma-Associated Anemia. Acta Haematol 1997; 98:204-210.

  22. Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant Human Erythropoietin for the Treatment of Chronic Anemia in Multiple Myeloma and Squamous Cell Carcinoma. Stem cells 1993; 11:348-355.

  23. Escala de analgesia del dolor. Disponible en: http://www.who.int/cancer/palliative/painladder/en/index.html

  24. Disponible en:http://www.facmed.unam.mx/bmnd/gi_2k8/prods/PRODS/Furosemida.htm

  25. Disponible en:http://www.saludzac.gob.mx/plm/prods/36630.htm

  26. Disponible en: http://www.facmed.unam.mx/bmnd/dirijo.php?bib_vv=6

  27. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or steolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.

  28. Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002:119, 496-499.

  29. Chang JM, Green L, Beitz J. Renal failure with the use of Zoledronic Acid . N Engl J Med 2003; 349:1676-1678.

  30. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Inter 2004; 65:634-641.

  31. Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypercalcemia in thalidomide-treated myeloma patients receiving zoledronic acid infusion. Bri J Haematol 2002; 119: 576-577.

  32. Heinz L, Johannes D, Helmut G, Alois L, Johannes G. Reversal of acute failure by bortezomib-based chemotherapy in patients with multiple myeloma. Hematologica 2007; 92:1411-1414.

  33. Knusden LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma –a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53:207-212.

  34. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Inter Med 1990; 150:1693-5.

  35. Winerals CG. Acute myeloma kidney. Kidney Int 1995; 48: 1347-1361.

  36. Clark AD, Shelty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999; 13:79-90.

  37. Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982; 96: 47-50.

  38. Towmey JJ. Infections complicating multiple myeloma and chronic lymphocitic leukemia. Arch Intern Med 1973;132:562-565.

  39. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981;71:935-940.

  40. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood, 2000; 95: 7-11.

  41. Jacobson DR, Zolla-Pazner S. Immunosuppresion and infection in multiple myeloma. Semin Oncol 1986;13:282-290.

  42. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic, factors and disease complications in a single centre between 1975 and 1988. Q J Med 1991;79:517-525.

  43. Chapel JM, Lee M, Hargreaves R, Pamphilon DH, Prentince AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343:1059-1063.

  44. Kyle RA, Disperienzi A. Neurological aspects of monoclonal gammopathy of undetermined significance, multiple myeloma, and related disorders. In: Multiple Myeloma and Related Disorders. G. Gahtron, B.G.M. Durie & D. Samson, Arnold, London, 2004;p:350-365.

  45. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.

  46. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hullin C, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologus stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial. American Society for Oncology Annual Meeting. Chicago, Illinois. J Clin Oncol 2008;26(18S).

  47. Oakervee H, Popat R, Cavenagh JG. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 2007;48:1910-1921.

  48. Popat R, Oakervee H, Hallam S, Curry N, Odeh L, Foot N, et al. Bortezomib, doxorubicin and dexamethasone (PAD) fron-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512-516.

  49. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-2042.

  50. Facon T, Mary J, Harousseau J, Huguet F, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. American Society for Clinical Oncology Annual Meeting. Atlanta, Georgia. J Clin Oncol 2006;24(18S).

  51. Palumbo A, Bringhen S, Caravita T, Musto P, Capparella V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 2:825-831.

  52. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in early untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-2172.

  53. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 2008; 359:906-917.

  54. Durie BG, Kyle RA, Belch A, Besinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus re- port from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-398.

  55. Ferlay J, Bray F, Pisani P, Parkin DM, Globocan 2000. World Health Organization, International Agency for Research on Cancer. Available from: http://www.emro.who.int/ncd/cancer_globocan.htm

  56. Orlowski RZ. Initial therapy of Multiple Myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2006:338-47.

  57. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103:1195-1200.

  58. Multiple Myeloma and other plasma cell neoplasms treatment. National Cancer Institute, U S 2008. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/HealthProfessional/page7

  59. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006;47:803-814.

  60. Shaughnessy JD, Zhan F, Burington BE, Huang Y, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284.

  61. Morgan TK, Zhao S, Chang KL, Haddix TL, Domanay E, Cornbleet J, et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol 2006;126:545-551.

  62. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma. Blood 2006;108:123a-124a.

  63. Alexanian R, Weber D, Giralt S, Dimopulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;127:1037-1043.

  64. Harousseau JL, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau, et al. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM). Combine results of the IFM 99 trials. Blood 2006;108:877a

  65. Disponible en: http://www.nutricionhospitalaria.com/mostrarfile. asp?ID=4305

  66. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria. Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.

  67. Ludwig H, Zojer N. Aspirin supportive care in multiple myeloma. Best Practices & Research Clinical Haematology FALTA EL AÑO 20:817-835.

  68. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs 2005;14:1411-1418.

  69. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide-andlenalidomide associated thrombosis in myeloma. Leukemia 2008;22:414-423.

  70. Vela Ojeda J, García-Ruíz Esparza MA, Padilla-González Y, Gómez-Almaguer D, Gutiérrez-Aguirre CH, Gómez-Rangel D, et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus IV melaphan. Ann Hematol 2007; 86:277-282.

  71. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.: A simplified method for stem cell autografting in multiple myeloma: A single institution experience. Bone Marrow Transplant 2009, Apr 6 [Epub ahead of print].

  72. Reyes-Torres V, Hernández-Arizpe A, López-Otero A, Ruiz-Delgado G, Kramis-Cerezo JL, Ruiz-Argüelles GJ. El AMD3100 (plerixafor) puede mejorar la movilización de células hematopoyéticas para hacer trasplantes autólogos. Informe de un caso. Medicina Univ 2009; 11:202-206.

  73. Ruiz-Arguelles GJ. Whither the bone marrow transplant. Hematology 2010;15:1-3.

  74. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath W (Jr). Cancer statistics by race and ethnicity. CA Cancer J Clin 1998;48:31-48.




2020     |     www.medigraphic.com